Piacente et al. hypothesized that alternative NAD production routes could represent a mechanism of tumor resistance to NAMPT inhibitors and demonstrated that the Preiss–Handler pathway gene, NAPRT, is frequently amplified and overexpressed in a subset of human tumors such as ovarian, breast, pancreatic, and prostate cancer. This evidence concerns the gene NAMPT and prostate carcinoma.